Comparative Effectiveness Hits Medical Devices
Executive Summary
Converging provider, payor and regulatory forces are making comparative effectiveness and evidence of value top priority issues for device companies. This article was excerpted from the March 2010 issue of In Vivo.
You may also be interested in...
Medical Device Regulation: Change is in the Air
As the FDA revamps the medical device approval process, significant overhauls are expected for both the PMA and 510(k) pathways. Medtech Insight is presenting a series of articles focusing on the effect these changes will have to the industry, starting with this first installment focused on potential changes to premarket approvals.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.